Jeffrey F Waring

Development of a toxicogenomics in vitro assay for the efficient characterization of compounds.

J. Waring, R. Ciurlionis, Yi Yang, 2006, Pharmacogenomics.

Use of traditional end points and gene dysregulation to understand mechanisms of toxicity: toxicogenomics in mechanistic toxicology.

J. Waring, E. Blomme, Eric A Blomme, 2008, Methods in molecular biology.

Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions

Michael J Liguori, J. Waring, M. Liguori, 2006, Expert opinion on drug metabolism & toxicology.

Toxicogenomics in drug discovery: from preclinical studies to clinical trials.

Eric A G Blomme, J. Waring, E. Blomme, 2004, Chemico-biological interactions.

Modest Inflammation Enhances Diclofenac Hepatotoxicity in Rats: Role of Neutrophils and Bacterial Translocation

Michael J Liguori, Eric A G Blomme, J. Waring, 2006, Journal of Pharmacology and Experimental Therapeutics.

Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans

J. Waring, U. Warrior, D. Burns, 2008, Journal of biomolecular screening.

Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.

Xudong Dai, Yudong D. He, Guy Cavet, 2007, Genomics.

The promise of toxicogenomics.

J. Waring, D. Halbert, Jeffrey F Waring, 2002, Current opinion in molecular therapeutics.